Hikma Pharmaceuticals has named Surendera Tyagi, Ph.D., as its CSO and global head of R&D. Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when its generic drug unit is suffering.
The CSO is joining Hikma from Fresenius Kabi. Tyagi joined Fresenius Kabi in 2008 and went on to expand its cancer business and take charge of a U.S. innovation and development center. Earlier in his career Tyagi held positions at companies including Dabur Pharma, Roche, IGEN, Abbott and Schwarz Pharma.
Hikma hopes to tap into the experience Tyagi accrued in these roles to expand its pipeline and accelerate the progress of its top prospects. For the first year, Tyagi will focus on the noninjectable side of Hikma’s business.
Tyagi’s appointment follows a 12-month period in which Hikma’s stock fell by more than 40%. Investors drove down the price of the stock throughout the last nine months of 2017 as news of the difficulties of bringing a generic version of GlaxoSmithKline’s Advair to market in the U.S. and the woes of the broader off-patent unit dripped out.
Hikma sees research and innovation as one of the ways to dig itself out of its current predicament. And it views Tyagi as the right person to execute this part of its growth strategy.
“Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world’s largest and most successful pharmaceutical organizations,” Hikma CEO Saïd Darwazah said in a statement. “Research and Innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy.”
By Nick Paul Taylor
Source: Fierce Biotech
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
